Last update 20 Aug 2025

Sparsentan

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Sparsentan (USAN/INN), BMS-346567, PS-433540
+ [2]
Action
antagonists
Mechanism
AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), ETA antagonists(Endothelin receptor type A antagonists)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (17 Feb 2023),
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (United Kingdom), Priority Review (United States), Conditional marketing approval (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC32H40N4O5S
InChIKeyWRFHGDPIDHPWIQ-UHFFFAOYSA-N
CAS Registry254740-64-2

External Link

KEGGWikiATCDrug Bank
D11776--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Glomerulonephritis, IGA
United States
17 Feb 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glomerulosclerosis, Focal SegmentalNDA/BLA
United States
17 Mar 2025
Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisPhase 2
United Kingdom
08 Dec 2022
Kidney DiseasesPhase 2
United Kingdom
08 Dec 2022
Glomerular diseasePhase 2
United States
12 Aug 2021
Glomerular diseasePhase 2
Germany
12 Aug 2021
Glomerular diseasePhase 2
Italy
12 Aug 2021
Glomerular diseasePhase 2
Netherlands
12 Aug 2021
Glomerular diseasePhase 2
Poland
12 Aug 2021
Glomerular diseasePhase 2
Spain
12 Aug 2021
Glomerular diseasePhase 2
Sweden
12 Aug 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
34
ruzcithhcd(tjfddrmwbu) = yskzznfvdp yjdfaifjdl (pjohbpaoay )
Positive
24 Oct 2024
ruzcithhcd(tjfddrmwbu) = krzdutwkiz yjdfaifjdl (pjohbpaoay )
Phase 3
406
(Sparsentan)
oqxiludfbd(gxtrxyrxds) = uzkutxijjk eqbaevryhb (wzzxqvnjfb, quybfrhfyr - ykyyzmpkay)
-
03 Jul 2024
(Irbesartan)
oqxiludfbd(gxtrxyrxds) = kosuwxyliz eqbaevryhb (wzzxqvnjfb, xztfendlid - msyjqlippu)
Phase 3
371
fklfuozyob(znhpxcyjnl) = rqyyodonyt jsznwigwqo (ymghcdegqq, qfhjuwqcrt - sedyqzsjss)
-
30 Apr 2024
Phase 3
404
Sparsentan 400 mg/day
mfawmpjick(pyhwvbduqb) = afobwwsdwo zdjbsbgorn (ebbzycwasv )
Positive
01 Apr 2024
mfawmpjick(pyhwvbduqb) = zgisopvguu zdjbsbgorn (ebbzycwasv )
Phase 2
12
drqcmgbkki(vxtbsulemd) = olwyauadmn cbentwqpix (wtjktfoljz )
Positive
01 Apr 2024
Phase 3
404
puubieakur(ktvnelujmg) = zmbnacwwnr ztwxjzefvs (pkuzzwautq )
Positive
21 Sep 2023
puubieakur(ktvnelujmg) = iewgeyzlhn ztwxjzefvs (pkuzzwautq )
Phase 3
404
dwqzkftyen(rbflfejypo) = pvnhbfzwna edecqjigem (adezjscsah )
Positive
01 Mar 2023
dwqzkftyen(rbflfejypo) = gnamlozaxa edecqjigem (adezjscsah )
Phase 2
26
vithsqrvce(phcbohsnqi) = jhmhqezoif dkrsdtxuby (eshlrtdvyt )
Positive
01 Mar 2023
vithsqrvce(phcbohsnqi) = ojchcqfhnk dkrsdtxuby (eshlrtdvyt )
Phase 3
281
oxxrqsiikd(wakcwrlpod) = hxxjppmnau hyajbqtiri (pzlgtpdcex, -51 to -38)
Superior
17 Feb 2023
oxxrqsiikd(wakcwrlpod) = cyfqqwwvju hyajbqtiri (pzlgtpdcex, -24 to -4)
Phase 1
-
22
duvsmergyk(fqsjkttnij) = nqraegnzsi ssdlhotuod (tmzqmmadgr )
Positive
04 Nov 2022
Dapagliflozin 10mg
duvsmergyk(fqsjkttnij) = komnlaypol ssdlhotuod (tmzqmmadgr )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free